Brave Asset Management’s Novavax NVAX Stock Holding History

Brave Asset Management’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-13,000	Closed	-$62.1K	–	165
2024 Q1	$62.1K	Buy	+13,000	New	+$60.3K	0.02%	147

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Brave Asset Management's NVAX Position: Q2 2024 in Review

Brave Asset Management sold out of Novavax (NVAX) in Q2 2024, closing a stake of 13,000 shares — an estimated $62.1K sold.

Brave Asset Management first reported a position in NVAX in Q1 2024 and held it in 1 quarter. The position peaked at $62.1K in Q1 2024. 229 funds tracked by Wall St. Rank hold NVAX as of Q2 2024.

Brave Asset Management reported no remaining Novavax position as of Q2 2024 after selling out during the quarter.
Brave Asset Management sold 13,000 Novavax shares in Q2 2024, an estimated $62.1K.
Brave Asset Management first reported a position in Novavax in Q1 2024 and held it in 1 quarter.
Brave Asset Management's Novavax position peaked at $62.1K in Q1 2024.
229 funds tracked by Wall St. Rank held Novavax as of Q2 2024.

Based on Brave Asset Management's 13F filing for Q2 2024, filed 15 Jul 2024.